WCWei Chen

Wei Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Chen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Changming Yu

    Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China

    1 shared publication
  • Lei Dong

    Clinical Laboratory Center, PLA Air Force General Hospital, Haidian, Beijing 100142

    1 shared publication
  • Lihua Hou

    Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China

    1 shared publication
  • Ling Fu

    Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China

    1 shared publication
  • Shaoqiong Yi

    Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China

    1 shared publication
  • Shuling Liu

    Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    Monitoring luciferase-labeled human prostate stem cell antigen-expressing tumor growth in a mouse model

    by Lei Dong, Xiaopeng Zhang, Changming Yu, Ting Yu, Shuling Liu, Lihua Hou, Ling Fu, Shaoqiong Yi, Wei Chen

    The aim of this study was to establish a tumor model in mice with the expression of luciferase (Luc) and human prostate stem cell antigen (PSCA), in order to evaluate the activities of anticancer drugs or vaccines for prostate cancer. RM-1 cells were stably transfected with pcDNA-Luc and pcDNA-PSCA plasmids. The Luc-expressing cells were examined using a luminometer and the PSCA-expressing cells were examined using a reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometric analysis. Male C57BL/6 mice were inoculated subcutaneously with the RM-PSCA/Luc cells, prior to the tumor growth and survival time of the mice being measured, respectively. In vivo bioluminescence imaging was used to detect Luc expression and immunohistochemical analysis was used to detect PSCA expression. Inoculation of the tumor cells into the C57BL/6 mice closely mimicked the tumor growth of prostate cancer. All of the inoculated mice exhibited a detectable tumor within two weeks. Tumor progression was able to be quantitatively monitored following the inoculation of 1×106 RM-PSCA/Luc cells. There was an excellent correlation (R2=0.9849) between the photon counts and tumor volume. The expression of PSCA in tumor tissues was confirmed using immunohistochemical analysis. The Luc and PSCA co-expression tumor model was successfully established in mice, which is likely to accelerate the understanding of the pathogenesis of prostate cancer and facilitate the development of novel antitumor drugs or vaccines for the disease.